Anlotinib: all 260 studies that test it

Page 2 of 3. Open to participants first (104), then studies with results posted, then the rest; newest registration first within each.

• Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)RecruitingNCT04278222Phase 2
• Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLCRecruitingNCT04136535Phase 2
• Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save StudyRecruitingNCT03646968Phase 2
• Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)RecruitingNCT03016819Phase 3
• Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast CancerActive, not recruitingNCT05558722Phase 2Results posted
• Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell CarcinomaActive, not recruitingNCT07881900Phase 3
• Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLCActive, not recruitingNCT07703228Phase 2
• Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract CancerActive, not recruitingNCT07635290Phase 2
• Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRTCompletedNCT07037680Phase 2
• A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 ExpressionActive, not recruitingNCT06939452Phase 2
• A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 TabletsTerminatedNCT06507891Phase 1/2
• The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric JunctionStatus unknownNCT06396585Phase 2
• Anlotinib Capsules in the Treatment for IPF/PF-ILDsActive, not recruitingNCT05828953Phase 2
• Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT05816499Phase 1/2
• Anlotinib and Radiotherapy in Resectable Soft Tissue SarcomaStatus unknownNCT05602415Phase 2
• A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer.CompletedNCT05493995Phase 2
• Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung CancerWithdrawnNCT05481775Phase 2
• Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 InhibitorsStatus unknownNCT05460481Phase 2
• Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With AnlotinibStatus unknownNCT05453383Phase 2
• Niraparib Plus Anlotinib for Recurrent Ovarian CancerStatus unknownNCT05311579Phase 2
• A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue SarcomaCompletedNCT05301764Phase 1/2
• Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)Status unknownNCT05262335Phase 2
• Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell CarcinomaActive, not recruitingNCT05220267Phase 2
• Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast CancerCompletedNCT05206656Phase 2
• AK105 Combined With Anlotinib in Patients With Cervical CancerActive, not recruitingNCT05137171Phase 2
• A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory TrialStatus unknownNCT05133349Phase 2
• Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.CompletedNCT05130515Phase 2
• Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant MelanomaStatus unknownNCT05087602Phase 2
• Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)Active, not recruitingNCT05038813Phase 2
• Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.Status unknownNCT05033587Phase 2
• Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial CarcinomaStatus unknownNCT05030077Phase 2
• TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.Status unknownNCT05013697Phase 2
• Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based ChemotherapyCompletedNCT05001971Phase 2
• Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1Status unknownNCT04999800Phase 2
• Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)CompletedNCT04996758Phase 2
• To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.Active, not recruitingNCT04985851Not applicable
• Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of MelanomaStatus unknownNCT04979585Phase 2
• the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung CancerStatus unknownNCT04978753Phase 2
• ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast CancerStatus unknownNCT04975451Phase 2
• Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003Status unknownNCT04970914Phase 2
• Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC PatientsCompletedNCT04967079Phase 1
• Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT)CompletedNCT04963088Phase 1/2
• Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung CancerStatus unknownNCT04933175Phase 2
• Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLCStatus unknownNCT04895930Phase 2
• The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBCCompletedNCT04877821Phase 2
• Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT04813406Not applicable
• Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian CancerActive, not recruitingNCT04807166Phase 2
• Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic CancerStatus unknownNCT04803851Phase 1/2
• Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLCStatus unknownNCT04797806Phase 3
• SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell CancerStatus unknownNCT04797507Phase 2
• Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon MutationsCompletedNCT04790409Phase 2
• Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal CancerStatus unknownNCT04777162Phase 2
• Advanced Lung Tumor Treated by Osimertinib Plus AnlotinibCompletedNCT04770688Phase 1/2
• Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue SarcomaStatus unknownNCT04765228Phase 2
• Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid TumorsStatus unknownNCT04764084Phase 1
• Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung CancerStatus unknownNCT04731909Not applicable
• Combination Therapy for First Line Treatment of Advanced Cervical CancerStatus unknownNCT04731038Phase 1
• Anlotinib Combined With STUPP for MGMT Nonmethylated GlioblastomaStatus unknownNCT04725214Phase 2
• Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic CancerStatus unknownNCT04718701Phase 2
• Anlotinib to Malignant Brainstem GliomaStatus unknownNCT04668508Phase 2
• Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCCStatus unknownNCT04665609Phase 3
• A Trial of AK104 Plus Anlotinib in NSCLCCompletedNCT04646330Phase 1/2
• Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal CancerWithdrawnNCT04620473Phase 2
• A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial CancerCompletedNCT04574284Phase 2
• Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian CancerStatus unknownNCT04566952Phase 2
• A Study of Combination Therapy in NSCLCStatus unknownNCT04544644Phase 2
• A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal CancerActive, not recruitingNCT04523272Phase 3
• Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.Status unknownNCT04453423Phase 2
• Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast CancerStatus unknownNCT04452370Phase 2
• A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)Status unknownNCT04405505Phase 3
• Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian CancerStatus unknownNCT04376073Phase 2
• Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With GefitinibStatus unknownNCT04358562Phase 2
• A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)Status unknownNCT04325763Phase 3
• Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib ResistanceStatus unknownNCT04316351Phase 2
• Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid CancerStatus unknownNCT04309136Phase 2
• Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract CancerStatus unknownNCT04300959Phase 2
• A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid TumorStatus unknownNCT04291248Phase 2
• Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)CompletedNCT04271813Phase 2
• A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological CancerStatus unknownNCT04236362Phase 1/2
• A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)Status unknownNCT04234607Phase 3
• Anlotinib Treatment in Steroid Depenent/Refractory cGVHDTerminatedNCT04232397Phase 2
• Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT04229849Phase 2
• A Study of Anlotinib in Subjects With Advanced MalignancyCompletedNCT04216082Phase 2
• Anlotinib Combined With Nivolumab for Non-Small Cell Lung CancerStatus unknownNCT04211896Phase 2
• A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine TumorsStatus unknownNCT04207463Phase 2
• A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest CancerStatus unknownNCT04203719Phase 2
• Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade GliomasActive, not recruitingNCT04197492Phase 2
• Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue SarcomaCompletedNCT04172805Phase 2
• Evaluation of AL3818 in Combination With Nivolumab in Solid TumorsActive, not recruitingNCT04165330Phase 1/2
• Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung CancerStatus unknownNCT04164745Phase 2
• Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCCStatus unknownNCT04157140Phase 2
• Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLCStatus unknownNCT04147728Phase 2
• Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)Status unknownNCT04124731Phase 2
• Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter TrialStatus unknownNCT04106024Phase 2
• Study of Anlotinib After Lenvatinib in Patients With Hepatocellular CarcinomaStatus unknownNCT04080154Phase 2
• Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung CancerStatus unknownNCT04073550Phase 3
• Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung CancerStatus unknownNCT04073537Phase 3
• Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04052152Phase 2
• Clinical Study on the Treatment of Recurrent Glioblastoma With AnlotinibStatus unknownNCT04004975Phase 1/2
• Study of TQB2450 Combined With Anlotinib in Subjects With Advanced CholangiocarcinomaStatus unknownNCT03996408Phase 1/2

← Anlotinib overview